SPOTLIGHT: Novalar approval a small gain for big group


Novalar Pharmaceuticals may not have made drug history when the FDA approved their new therapy to speed the return of sensation after dental procedures, but the private biotech has some ambitious plans for marketing the drug. OraVerse goes on sale this fall at $12.50 a shot, promising to cut the amount of time spent drooling by about 75 to 85 minutes. Some people might call it trivial, but the experts say it addresses a real need. OraVerse release | Report

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.